Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner

Journal of Virology

Volumn 84, Issue 12, 2010, Pages 6139-6152

  Ellis, Amy L ^a   Wang, Zhenxun ^a   Yu, Xianming ^a   Mertz, Janet E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS PROTEIN; ZINC FINGER E BOX BINDING PROTEIN 1; ZINC FINGER E BOX BINDING PROTEIN 2; ZINC FINGER PROTEIN;

ARTICLE; B LYMPHOCYTE; CELL TYPE; CONTROLLED STUDY; EPITHELIUM CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; LYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS LATENCY; VIRUS REACTIVATION;

BASE SEQUENCE; CELL LINE; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HOMEODOMAIN PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; REPRESSOR PROTEINS; SPECIES SPECIFICITY; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

HUMAN HERPESVIRUS 4;

EID: 77952677694     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02706-09     Document Type: Article

References (85)

1. Adamson, A. L., and S. Kenney. 2001. Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J. Virol. 75:2388-2399.
2. Beral, V., T. Peterman, R. Berkelman, and H. Jaffe. 1991. AIDS-associated non-Hodgkin lymphoma. Lancet 337:805-809.
3. Bindels, S., M. Mestdagt, C. Vandewalle, N. Jacobs, L. Volders, A. Noël, F. van Roy, G. Berx, J. M. Foidart, and C. Gilles. 2006. Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene 25:4975-4985. (Pubitemid 44246356)
4. Binné, U. K., W. Amon, and P. J. Farrell. 2002. Promoter sequences required for reactivation of Epstein-Barr virus from latency. J. Virol. 76:10282-10289.
5. Borras, A. M., J. L. Strominger, and S. H. Speck. 1996. Characterization of the ZI domains in the Epstein-Barr virus BZLF1 gene promoter: role in phorbol ester induction. J. Virol. 70:3894-3901.
6. Bracken, C. P., P. A. Gregory, N. Kolesnikoff, A. G. Bert, J. Wang, M. F. Shannon, and G. J. Goodall. 2008. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 68:7846-7854.
7. Burk, U., J. Schubert, U. Wellner, O. Schmalhofer, E. Vincan, S. Spaderna, and T. Brabletz. 2008. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 9:582-589. (Pubitemid 351772923)
8. Cahir-McFarland, E. D., K. Carter, A. Rosenwald, J. M. Giltnane, S. E. Henrickson, L. M. Staudt, and E. Kieff. 2004. Role of NF-κB in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J. Virol. 78:4108-4119.
9. Chang, Y. N., D. L. Dong, G. S. Hayward, and S. D. Hayward. 1990. The Epstein-Barr virus Zta transactivator: a member of the bZIP family with unique DNA-binding specificity and a dimerization domain that lacks the characteristic heptad leucine zipper motif. J. Virol. 64:3358-3369.
10. Christoffersen, N. R., A. Silahtaroglu, U. A. Ørom, S. Kauppinen, and A. H. Lund. 2007. MiR-200b mediates post-transcriptional repression of ZFHX1B. RNA 13:1172-1178.
11. Comijn, J., G. Berx, P. Vermassen, K. Verschueren, L. van Grunsven, E. Bruyneel, M. Mareel, D. Huylebroeck, and F. van Roy. 2001. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell 7:1267-1278. (Pubitemid 32607360)
12. Countryman, J., H. Jenson, R. Seibl, H. Wolf, and G. Miller. 1987. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J. Virol. 61:3672-3679. (Pubitemid 18011461)
13. Countryman, J., and G. Miller. 1985. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. U. S. A. 82:4085-4089.
14. Delecluse, H. J., T. Hilsendegen, D. Pich, R. Zeidler, and W. Hammerschmidt. 1998. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc. Natl. Acad. Sci. U. S. A. 95:8245-8250.
15. Desgranges, C., H. Wolf, G. De-Thé, K. Shanmugaratnam, N. Cammoun, R. Ellouz, G. Klein, K. Lennert, N. Muñoz, and H. Zur Hausen. 1975. Nasopharyngeal carcinoma. X. Presence of Epstein-Barr genomes in separated epithelial cells of tumours in patients from Singapore, Tunisia and Kenya. Int. J. Cancer 16:7-15.
16. Dickerson, S. J., Y. Xing, A. R. Robinson, W. T. Seaman, H. Gruffat, and S. C. Kenney. 2009. Methylation-dependent binding of the Epstein-Barr virus BZLF1 protein to viral promoters. PLoS Pathog. 5:e1000356.
17. Dirmeier, U., B. Neuhierl, E. Kilger, G. Reisbach, M. L. Sandberg, and W. Hammerschmidt. 2003. Latent membrane protein 1 is critical for efficient growth transformation of human B cells by Epstein-Barr virus. Cancer Res. 63:2982-2989. (Pubitemid 36667173)
18. Eger, A., K. Aigner, S. Sonderegger, B. Dampier, S. Oehler, M. Schreiber, G. Berx, A. Cano, H. Beug, and R. Foisner. 2005. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24:2375-2385. (Pubitemid 40546696)
19. Epstein, M. A., B. G. Achong, and Y. M. Barr. 1964. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet i:702-703.
20. Feederle, R., M. Kost, M. Baumann, A. Janz, E. Drouet, W. Hammerschmidt, and H. J. Delecluse. 2000. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 19:3080-3089. (Pubitemid 30386778)
21. Feng, W. H., J. I. Cohen, S. Fischer, L. Li, M. Sneller, R. Goldbach-Mansky, N. Raab-Traub, H. J. Delecluse, and S. C. Kenney. 2004. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J. Natl. Cancer Inst. 96:1691-1702.
22. Feng, W. H., G. Hong, H. J. Delecluse, and S. C. Kenney. 2004. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J. Virol. 78:1893-1902.
23. Feng, W. H., B. Israel, N. Raab-Traub, P. Busson, and S. C. Kenney. 2002. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res. 62:1920-1926.
24. Feng, W. H., and S. C. Kenney. 2006. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res. 66:8762-8769.
25. Feng, W. H., R. J. Kraus, S. J. Dickerson, H. J. Lim, R. J. Jones, X. Yu, J. E. Mertz, and S. C. Kenney. 2007. ZEB1 and c-Jun levels contribute to the establishment of highly lytic Epstein-Barr virus infection in gastric AGS cells. J. Virol. 81:10113-10122.
26. Flemington, E., and S. H. Speck. 1990. Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol. 64:1217-1226. (Pubitemid 20087760)
27. Genetta, T., D. Ruezinsky, and T. Kadesch. 1994. Displacement of an E-box-binding repressor by basic helix-loop-helix proteins: implications for B-cell specificity of the immunoglobulin heavy-chain enhancer. Mol. Cell. Biol. 14:6153-6163.
28. Glaser, R., H. Y. Zhang, K. T. Yao, H. C. Zhu, F. X. Wang, G. Y. Li, D. S. Wen, and Y. P. Li. 1989. Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc. Natl. Acad. Sci. U. S. A. 86:9524-9528.
29. Gradoville, L., D. Kwa, A. El-Guindy, and G. Miller. 2002. Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle. J. Virol. 76: 5612-5626. (Pubitemid 34517912)
30. Gregory, C. D., M. Rowe, and A. B. Rickinson. 1990. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J. Gen. Virol. 71(part 7):1481-1495.
31. Gregory, P. A., A. G. Bert, E. L. Paterson, S. C. Barry, A. Tsykin, G. Farshid, M. A. Vadas, Y. Khew-Goodall, and G. J. Goodall. 2008. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10:593-601.
32. Gregory, P. A., C. P. Bracken, A. G. Bert, and G. J. Goodall. 2008. Micro-RNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 7:3112-3118.
33. Gruffat, H., E. Manet, and A. Sergeant. 2002. MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling. EMBO Rep. 3:141-146. (Pubitemid 34213491)
34. Hammerschmidt, W., and B. Sugden. 2004. Epstein-Barr virus sustains Burkitt's lymphomas and Hodgkin's disease. Trends Mol. Med. 10:331-336.
35. Hammerschmidt, W., and B. Sugden. 1988. Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell 55:427-433. (Pubitemid 18261432)
36. Hinuma, Y., M. Konn, J. Yamaguchi, D. J. Wudarski, J. R. Blakeslee, Jr., and J. T. Grace, Jr. 1967. Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J. Virol. 1:1045-1051.
37. Jenkins, P. J., U. K. Binné, and P. J. Farrell. 2000. Histone acetylation and reactivation of Epstein-Barr virus from latency. J. Virol. 74:710-720. (Pubitemid 30036207)
38. Jung, E. J., Y. M. Lee, B. L. Lee, M. S. Chang, and W. H. Kim. 2007. Lytic induction and apoptosis of Epstein-Barr virus-associated gastric cancer cell line with epigenetic modifiers and ganciclovir. Cancer Lett. 247:77-83. (Pubitemid 44959412)
39. Korpal, M., E. S. Lee, G. Hu, and Y. Kang. 2008. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 283:14910-14914.
40. Kraus, R. J., S. J. Mirocha, H. M. Stephany, J. R. Puchalski, and J. E. Mertz. 2001. Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus. J. Virol. 75:867-877.
41. Kraus, R. J., J. G. Perrigoue, and J. E. Mertz. 2003. ZEB negatively regulates the lytic-switch BZLF1 gene promoter of Epstein-Barr virus. J. Virol. 77:199-207.
42. Lee, D. Y., and B. Sugden. 2008. The latent membrane protein 1 oncogene modifies B-cell physiology by regulating autophagy. Oncogene 27:2833-2842.
43. Lee, D. Y., and B. Sugden. 2008. The LMP1 oncogene of EBV activates PERK and the unfolded protein response to drive its own synthesis. Blood 111:2280-2289.
44. Lieberman, P. M., and A. J. Berk. 1990. In vitro transcriptional activation, dimerization, and DNA-binding specificity of the Epstein-Barr virus Zta protein. J. Virol. 64:2560-2568.
45. Lin, J. C., J. E. Shaw, M. C. Smith, and J. S. Pagano. 1979. Effect of 12-O-tetradecanoyl-phorbol-13-acetate on the replication of Epstein-Barr virus. I. Characterization of viral DNA. Virology 99:183-187.
46. Liu, B. Y., Y. C. Kim, V. Leatherberry, P. Cowin, and C. M. Alexander. 2003. Mammary gland development requires syndecan-1 to create a β-catenin/TCF-responsive mammary epithelial subpopulation. Oncogene 22:9243-9253.
47. Liu, P., S. Liu, and S. H. Speck. 1998. Identification of a negative cis element within the ZII domain of the Epstein-Barr virus lytic switch BZLF1 gene promoter. J. Virol. 72:8230-8239. (Pubitemid 28421820)
48. Liu, S., A. M. Borras, P. Liu, G. Suske, and S. H. Speck. 1997. Binding of the ubiquitous cellular transcription factors Sp1 and Sp3 to the ZI domains in the Epstein-Barr virus lytic switch BZLF1 gene promoter. Virology 228:11-18. (Pubitemid 27238815)
49. Lo, A. K., K. F. To, K. W. Lo, R. W. Lung, J. W. Hui, G. Liao, and S. D. Hayward. 2007. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc. Natl. Acad. Sci. U. S. A. 104:16164-16169.
50. Manet, E., H. Gruffat, M. C. Trescol-Biemont, N. Moreno, P. Chambard, J. F. Giot, and A. Sergeant. 1989. Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators. EMBO J. 8:1819-1826. (Pubitemid 19273999)
51. Mentzer, S. J., J. Fingeroth, J. J. Reilly, S. P. Perrine, and D. V. Faller. 1998. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells Mol. Dis. 24:114-123.
52. Mentzer, S. J., S. P. Perrine, and D. V. Faller. 2001. Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl. Infect. Dis. 3:177-185.
53. Morrison, T. E., and S. C. Kenney. 2004. BZLF1, an Epstein-Barr virus immediate-early protein, induces p65 nuclear translocation while inhibiting p65 transcriptional function. Virology 328:219-232.
54. Nagase, T., H. Koga, and O. Ohara. 2006. Kazusa mammalian cDNA resources: towards functional characterization of KIAA gene products. Brief. Funct. Genomic. Proteomic. 5:4-7.
55. Nakajima, D., K. Saito, H. Yamakawa, R. F. Kikuno, M. Nakayama, R. Ohara, N. Okazaki, H. Koga, T. Nagase, and O. Ohara. 2005. Preparation of a set of expression-ready clones of mammalian long cDNAs encoding large proteins by the ORF trap cloning method. DNA Res. 12:257-267.
56. Nalesnik, M. A., R. Jaffe, T. E. Starzl, A. J. Demetris, K. Porter, J. A. Burnham, L. Makowka, M. Ho, and J. Locker. 1988. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am. J. Pathol. 133:173-192.
57. Park, S. M., A. B. Gaur, E. Lengyel, and M. E. Peter. 2008. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22:894-907.
58. Peinado, H., D. Olmeda, and A. Cano. 2007. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 7:415-428. (Pubitemid 46809165)
59. Peña, C., J. M. García, V. García, J. Sílva, G. Domínguez, R. Rodríguez, C. Maximiano, A. Garcia de Herreros, A. Muñoz, and F. Bonilla. 2006. The expression levels of the transcriptional regulators p300 and CtBP modulate the correlations between SNAIL, ZEB1, E-cadherin and vitamin D receptor in human colon carcinomas. Int. J. Cancer 119:2098-2104. (Pubitemid 44423667)
60. Postigo, A. A. 2003. Opposing functions of ZEB proteins in the regulation of the TGFβ/BMP signaling pathway. EMBO J. 22:2443-2452. (Pubitemid 36604983)
61. Postigo, A. A., and D. C. Dean. 2000. Differential expression and function of members of the zfh-1 family of zinc finger/homeodomain repressors. Proc. Natl. Acad. Sci. U. S. A. 97:6391-6396.
62. Postigo, A. A., and D. C. Dean. 1999. ZEB represses transcription through interaction with the corepressor CtBP. Proc. Natl. Acad. Sci. U. S. A. 96: 6683-6688.
63. Postigo, A. A., J. L. Depp, J. J. Taylor, and K. L. Kroll. 2003. Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins. EMBO J. 22:2453-2462.
64. Ragoczy, T., L. Heston, and G. Miller. 1998. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J. Virol. 72:7978-7984. (Pubitemid 28421790)
65. Ragoczy, T., and G. Miller. 2001. Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites. J. Virol. 75:5240-5251. (Pubitemid 32448547)
66. Rickinson, A. B., and E. Kieff. 2007. Epstein-Barr virus, p. 2603-2654. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
67. Robertson, E. S. 2005. Epstein-Barr virus. Caister Academic Press, Wymondham, England.
68. Sayan, A. E., T. R. Griffiths, R. Pal, G. J. Browne, A. Ruddick, T. Yagci, R. Edwards, N. J. Mayer, H. Qazi, S. Goyal, S. Fernandez, K. Straatman, G. D. D. Jones, K. J. Bowman, A. Colquhoun, J. K. Mellon, M. Kriajevska, and E. Tulchinsky. 2009. SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc. Natl. Acad. Sci. U. S. A. 106:14884-14889.
69. Schepers, A., D. Pich, and W. Hammerschmidt. 1993. A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus. EMBO J. 12:3921-3929. (Pubitemid 23282768)
70. Schepers, A., D. Pich, J. Mankertz, and W. Hammerschmidt. 1993. cis-Acting elements in the lytic origin of DNA replication of Epstein-Barr virus. J. Virol. 67:4237-4245. (Pubitemid 23180750)
71. Shibata, D., and L. M. Weiss. 1992. Epstein-Barr virus-associated gastric adenocarcinoma. Am. J. Pathol. 140:769-774.
72. Sinclair, A. J., M. Brimmell, F. Shanahan, and P. J. Farrell. 1991. Pathways of activation of the Epstein-Barr virus productive cycle. J. Virol. 65:2237-2244.
73. Takada, K., K. Horinouchi, Y. Ono, T. Aya, T. Osato, M. Takahashi, and S. Hayasaka. 1991. An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA. Virus Genes 5:147-156.
74. van Grunsven, L. A., A. Schellens, D. Huylebroeck, and K. Verschueren. 2001. SIP1 (Smad interacting protein 1) and δEF1 (δ-crystallin enhancer binding factor) are structurally similar transcriptional repressors. J. Bone Joint Surg. Am. 83:S40-S47.
75. Wang, J., S. Lee, C. E. Teh, K. Bunting, L. Ma, and M. F. Shannon. 2009. The transcription repressor, ZEB1, cooperates with CtBP2 and HDAC1 to suppress IL-2 gene activation in T cells. Int. Immunol. 21:227-235.
76. Wang, J., K. Scully, X. Zhu, L. Cai, J. Zhang, G. G. Prefontaine, A. Krones, K. A. Ohgi, P. Zhu, I. Garcia-Bassets, F. Liu, H. Taylor, J. Lozach, F. L. Jayes, K. S. Korach, C. K. Glass, X. D. Fu, and M. G. Rosenfeld. 2007. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 446:882-887. (Pubitemid 46633160)
77. Wang, Y. C., J. M. Huang, and E. A. Montalvo. 1997. Characterization of proteins binding to the ZII element in the Epstein-Barr virus BZLF1 promoter: transactivation by ATF1. Virology 227:323-330.
78. Weigel, R., and G. Miller. 1983. Major EB virus-specific cytoplasmic transcripts in a cellular clone of the HR-1 Burkitt lymphoma line during latency and after induction of viral replicative cycle by phorbol esters. Virology 125:287-298. (Pubitemid 13120107)
79. Weinmann, A. S., and P. J. Farnham. 2002. Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. Methods 26:37-47. (Pubitemid 34969216)
80. Weiss, L. M., J. G. Strickler, R. A. Warnke, D. T. Purtilo, and J. Sklar. 1987. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am. J. Pathol. 129:86-91.
81. Williams, T. M., D. Moolten, J. Burlein, J. Romano, R. Bhaerman, A. Godillot, M. Mellon, F. J. Rauscher III, and J. A. Kant. 1991. Identification of a zinc finger protein that inhibits IL-2 gene expression. Science 254:1791-1794.
82. Wu, F. Y., S. E. Wang, H. Chen, L. Wang, S. D. Hayward, and G. S. Hayward. 2004. CCAAT/enhancer binding protein α binds to the Epstein-Barr virus (EBV) ZTA protein through oligomeric interactions and contributes to cooperative transcriptional activation of the ZTA promoter through direct binding to the ZII and ZIIIB motifs during induction of the EBV lytic cycle. J. Virol. 78:4847-4865.
83. Yu, X., Z. Wang, and J. E. Mertz. 2007. ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus. PLoS Pathog. 3:e194.
84. Zalani, S., E. Holley-Guthrie, and S. Kenney. 1996. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc. Natl. Acad. Sci. U. S. A. 93:9194-9199.
85. zur Hausen, H., F. J. O'Neill, U. K. Freese, and E. Hecker. 1978. Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature 272: 373-375.